The once-daily investigational hepatitis C virus (HCV) combination tablet will likely be approved in 2017.

The drug improved several measures of liver disease severity among those with non-alcoholic steatohepatitis in a clinical trial.

Today’s teenagers are more likely to suffer from non-alcoholic steatophepatitis (NASH).

Biological members of the nuclear families of those with NAFLD are much more likely to have the condition as well.

The use of one of two nucleic acid polymers dramatically reduced hep B viral load among those with e-antigen-negative hepatitis B virus.

The relative simplicity of treating the virus with today’s treatments often means nonspecialist prescribers may provide sufficient care.

Individuals who develop liver cancer shortly after successful hepatitis C virus (HCV) treatment may have more aggressive cases.

Those who ate more meals per day and did not skip breakfast or lunch were less likely to develop nonalcoholic fatty liver disease.

However, the new triple combo’s results among those with genotype 1a of hep C were subpar.

Eight weeks of treatment had high cure rates among this hardest-to-treat group.